Compugen Ltd. is a pioneering, clinical-stage therapeutic discovery and development enterprise headquartered in Israel, recognized for utilizing a proprietary computational predictive discovery platform. By leveraging advanced algorithms, machine learning, and artificial intelligence, the company identifies novel drug targets and therapeutic candidates primarily focused on cancer immunotherapy, immune checkpoint inhibitors, and advanced myeloid-based treatment programs.